Table 3.
Combined IFN (recombinant or pegylated) + ribavirin therapy in HCV-related mixed cryoglobulinemia
| Author | Year | No. patients | Treatment | CS | Treatment duration (months) | EOT response | Sustained response |
| Durand | 1998 | 5 NR | RBV | No | 10-36 | 100% | 0% |
| Calleja | 1999 | 18 | 3 MIU IFN × 3/w | No | 12 | 55% | 28% |
| 8 NR | 3 MIU IFN × 3/w + RBV | No | 12 | 63% | 38% | ||
| Zuckerman | 2000 | 9 NR | 3 MIU IFN × 3/w + RBV | No | 6 | 78% | |
| Cacoub | 2002 | 14 | Variable IFN + RBV | variable | 6-56 | 71% | |
| Mazzaro | 2003 | 27 NR or Rel | 3 MIU × 3/w + RBV | No | 12 | 85% | |
| Alric | 2004 | 18 | 3 MIU × 3/w or Peg-IFN + RBV | No | ≥ 18 | 70% | |
| Cacoub | 2005 | 9 | Peg-IFN 1.5 μg Kg-1 w-1 + RBV | ≥ 10 | 88% | ||
| Mazzaro | 2005 | 18 | Peg-IFN 1 μg Kg-1 w-1 + RBV | No | 12 | 89% | 44% |
CS: corticosteroids; MIU: millions of international units; d: day; m: months; w: week; EOT: end of treatment; NR: non responders; Rel: relapser; RBV: ribavirin. From: Zignego A.L. Postgraduate Course of the 41st Annual Meeting of the EASL, 2006.